The Moroccan pharmaceutical company Sothema has announced a consolidated revenue of 1.328 billion Moroccan dirhams (MAD) for the first half of 2024, marking a 12.1% increase compared to the same period in 2023.
This impressive growth was driven by the strong commercial performance of Sothema and its subsidiaries, particularly Axess Pharma in Morocco and West Afric Pharma in Senegal, according to a company statement.
Sothema’s consolidated EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) reached 292 million MAD during the first six months of 2024, a 14.8% rise compared to June 2023. Additionally, the company invested 23 million MAD in the first half of the year, aimed at expanding its industrial and technological capabilities through various projects.
The company’s consolidated net debt rose to 394 million MAD by the end of June 2024, an increase of 106 million MAD compared to the same period last year. Despite this rise, the company’s overall financial performance remains robust, supported by continued investment and market expansion.
